Affordable Access

deepdyve-link
Publisher Website

Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells

Authors
  • Herrera, Victoria LM1, 2, 1, 2
  • Colby, Aaron H3, 3
  • Ruiz-Opazo, Nelson1, 2, 1, 2
  • Coleman, David G1, 1
  • Grinstaff, Mark W1, 3, 4, 1, 3, 4
  • 1 Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
  • 2 Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA
  • 3 Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA
  • 4 Department of Chemistry, Boston University, Boston, MA 02215, USA
Type
Published Article
Journal
Nanomedicine
Publisher
Future Medicine
Publication Date
Sep 11, 2018
Volume
13
Issue
16
Pages
2083–2098
Identifiers
DOI: 10.2217/nnm-2018-0122
PMID: 30204054
PMCID: PMC6219437
Source
PubMed Central
Keywords
License
Unknown

Abstract

An integrated analysis of the current-state-of-the-art in nucleic acid nanotherapies is presented with an emphasis on medical perspectives in nanomedicine.

Report this publication

Statistics

Seen <100 times